By using Semaglutide GLP-1 to regulate appetite and improve insulin response, Watson creates a foundation for steady fat reduction and improved metabolic health without extreme dieting
The acylation modification gives retatrutide a half-life of approximately six days, allowing once-weekly dosing, but that long half-life also means dosing errors compound over time rather than resolving quickly
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
Adiponectin levels increased in a time-related manner with higher doses of retatrutide, consistent with progressive adipose tissue reductions and improvements in insulin sensitivity 30
How do you know it's going to be safe? The truth is that these drugs have been evaluated in animals and patients for over 18 yearswe know a lot about them
